As of March 31, 2009, the company had cash of about $5,163,920 and short-term investments of about $480,005
Dwight Babcock, IsoRay chairman and chief executive officer, commented, Although, the quarter’ sales results were disappointing, we significantly narrowed our net loss while continuing to invest in new marketing and sales initiatives, such as the February 18, 2009 exclusive distribution agreement with BrachySciences. We continue to believe that we have the initiatives and personnel in place to improve sales growth and experience future operating improvements.
